We provide our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages.
MVMD is building a world-class biotech company centred around the implementation and licensing of our patented Quicksome™ oral delivery technologies across the global nutraceutical, vaccine and pharmaceutical landscape.
MVMD's underlying Quicksome™ technology has been in development since 2010, initially incorporated into several commercial dietary supplement products. To date, we have 14 patents in our patent portfolio, 12 extensions and have filed over a dozen provisional patents with respect to our Quicksome™ technology.
Mountain Valley MD Strategy
We are working against leading consumer propositions that offer increased bioavailability with rapid onset across the $2 trillion USD nutraceutical, vaccine and pharmaceutical industries.
MVMD’s advanced desiccated liposome formulations provide transmucosal delivery benefits across leading drug and vaccine application categories, including nutraceutical applications such as pain management, energy, focus, weight management, sleep, anxiety, and more.
Our Quicksome™ technology is available to leading nutraceutical, vaccine and pharmaceutical companies for license across a broad spectrum of molecules that provide unprecedented value propositions across their businesses.
Our focus on strategic distribution and licensing partnerships in key markets will enable us to leverage our intellectual property, establish licensing agreements and monetize our IP rapidly.
Across our delivery sciences IP portfolio and R&D work, MVMD prioritizes investment opportunities on disruptive technologies for health and wellness applications.
Our management team brings together world-class leadership across mucosal delivery sciences, molecular research, IP and legal management, marketing, distribution and financial services.